This article was originally published in The Gray Sheet
Results of a 100-patient trial of Cardica's C-Port distal anastomosis system for cardiac bypass are presented by Michael Mack, MD, Cardiothoracic Surgery Associates of North Texas at the European Association for Cardiothoracic Surgery/European Society of Thoracic Surgeons joint meeting in Leipzig, Germany Sept. 13. Patency of bypass vessels attached with C-Port was 96.9% after six months, compared to 84.9% in historical studies. Cardica, which is 20% owned by Guidant, will use the data to support a CE mark and 510(k) indication in the coming months, the firm says...
You may also be interested in...
Perrigo’s clinical trials on CBD likely will take years before resulting products help bring order to the market. During earnings presentation, CEO Murray Kessler says the trials aren’t intended to establish claims for CBD but are more a long-term effort to provide data to FDA.
As draft guidance receives OMB review, FDA’s determination of no economic significance reflects its official position that the thousands of supplements, food and personal care products containing CBDs available in the US are unlawful.
AdvaMed Accell executive director Ashley Wittorf spoke in support of a proposed US House bill that would give financial help to small companies making products to address COVID-19.